Evidence map›Paper›PMID 40225219›Full record

ArticleInternational journal of nanomedicine2025

The Selective in vitro Cytotoxicity of

Eliyahu Drori, Valeria Rahamim, Dhaval Patel, Yamm Anker, Sivan Meir, Gal Uzan, Chen Drori, Yaakov Anker, Aharon Azagury

Abstract read
In one paragraph

Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eliyahu DroriDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Valeria RahamimDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Dhaval PatelDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Yamm AnkerDepartment of Chemical Engineering, Ariel University, Ariel, Israel.ORCID 0009-0002-4311-0595
Sivan MeirDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Gal UzanDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Chen DroriDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Yaakov AnkerDepartment of Chemical Engineering, Ariel University, Ariel, Israel.
Aharon AzaguryDepartment of Chemical Engineering, Ariel University, Ariel, Israel.ORCID 0000-0002-5819-4106

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Cancer treatment often involves significant side effects, necessitating the need for more selective therapies. Methods: This study evaluated the cytotoxic effects of sNPs on cancer cell lines TR-146 (buccal), Caco-2 and HT-29 (colorectal), and MCF-7 (breast), compared to the non-cancerous MCF-10A cells. Cytotoxicity was assessed using the XTT assay at concentrations of 25-500 mg/mL over 3-48 hours. Cellular uptake was quantified via fluorescence-activated cell sorting (FACS) and fluorescence microscopy, and endocytic inhibitors were used to investigate the uptake mechanism. Results: sNPs induced 30-80% mortality in cancer cells, while non-cancerous MCF-10A cells exhibited negligible mortality (<5%). Male-derived Caco-2 cells were more sensitive to sNPs than female-derived HT-29 cells, suggesting potential sex-based differences. FACS analysis showed 100% cellular uptake in all cancer cells, with TR-146 exhibiting the highest fluorescence intensity. Endocytosis inhibition studies revealed that caveolae-mediated endocytosis played a significant role in sNP uptake, particularly in TR-146 and Caco-2 cells. Discussion: These findings demonstrate the potential of sNPs as selective and potent anticancer agents, warranting further research to optimize their clinical application.

Indexed as

Antineoplastic AgentsNanoparticlesNeoplasmsSpirulinaBiomimeticsCaco-2 CellsCell Line, TumorCell SurvivalEndocytosisFemaleHT29 CellsHumansMaleMCF-7 CellsAntineoplastic Agentsbiomimeticscancer therapycellular uptakeendocytic inhibitorsnanoparticlesSpirulina

Identifiers

PMID40225219
PMCPMC11992984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.